– USA, CA – Inogen, Inc. (NASDAQ: INGN), a medical technology company today announced the appointments of Glenn Boehnlein, Kevin King, and Mary Kay Ladone to its Board of Directors, effective March 22, 2022.
Concurrently, Heath Lukatch, Benjamin Anderson-Ray, and Loren McFarland retired from the Board.
“Maintaining a Board with diverse, fresh perspectives, skills, and experience to drive shareholder value is of utmost priority for Inogen and we are thrilled to welcome Glenn, Kevin, and Mary Kay to the Inogen Board. Each of them brings unique experiences and an extensive track record of helping guide and grow successful MedTech companies, which we believe positions them to support our overarching goal of transforming Inogen into a prominent leader in respiratory care.” said Board Chair, Elizabeth Mora.
About Glenn S. Boehnlein
Glenn Boehnlein currently serves as VP, CFO at Stryker Corporation (NYSE: SYK). In this role, Mr. Boehnlein is responsible for global finance activities which include corporate accounting, reporting, tax, treasury, and internal audit. Additionally, he is also responsible for global information technology and investor relations.
In 2003, Mr. Boehnlein began his career at Stryker as CFO for their Endoscopy division. Since then, he has served in roles of increasing responsibility at Stryker, including group CFO of MedSurg and Neurotechnology. Before joining Stryker, Mr. Boehnlein spent three years with MyPrimeTime as CFO, and before that, he was a partner and certified public accountant at Arthur Andersen.
Mr. Boehnlein holds a bachelor’s and master’s degree in accounting from Mississippi State University.
About Kevin King
Kevin King has over three decades of experience in the healthcare and IT industries in leadership roles. Until 2021, Mr. King served as CEO, President at iRhythm Technologies, Inc. (NASDAQ: IRTC). He recently announced his retirement from iRhythm’s Board of Directors.
Before joining iRhythm, Mr. King was President, CEO, and Director of Affymetrix, Inc. (now part of Thermo Fisher Scientific), a previously publicly-traded technology innovator in the field of genetic analysis, where he spent four years. Before joining Affymetrix in 2007, Mr. King served as President and CEO of Thomson Healthcare, an information services business, which focused on a range of healthcare-related businesses.
Mr. King also held several senior executive positions at GE Healthcare and began his career in HP’s Medical Products Group.
Mr. King has a bachelor’s degree in Economics and Biology from the University of Massachusetts and an M.B.A. from New Hampshire College. He also serves on the Board of two venture-backed healthcare companies, Cleerly Health and Flosonics.
About Mary Katherine Ladone
Mary Kay Ladone is an accomplished executive with over 30 years of experience serving large global healthcare companies. Until January 2022, Ms. Ladone served as Corporate Officer and SVP, Corporate Development, Strategy & Investor Relations at Hill-Rom Holdings, Inc., which is now a subsidiary of Baxter International, Inc. (NYSE: BAX).
Previously, Ms. Ladone served as SVP and Corporate Officer, Investor Relations of Baxalta, Inc., a global biopharmaceutical company spun out from Baxter International in 2015. She began her career in Finance at Baxter International and went on to serve in multiple financial, operational, and communication roles of increasing responsibility at the company including leading Baxter’s investor relations between 2004 and 2015.
Ms. Ladone has consistently been recognized by the investment community as top investor relations professional, including numerous designations by Institutional Investor. She currently is a member of the Board of Directors of Bioventus Inc. (NASDAQ: BVS), a global leader in innovations for active healing.
Ms. Ladone received a Bachelor of Business Administration degree (Finance & Business Economics) cum laude from the University of Notre Dame.
About Inogen
We are a medical technology company offering innovative respiratory products for use in the homecare setting. We primarily develop, manufacture and market innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
For more information: https://inogen.com/en
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
